Analyst firms · Stephens · EVH
Stephens EVH price target and rating history
Evolent Health Inc (EVH) · Consumer Discretionary
Stephens rates Evolent Health Inc (EVH) Overweight with a $7 price target, as of its latest action on Nov 13, 2025. It has published 3 rating actions on EVH since April 2023, including 1 upgrade and 1 downgrade. Across 4 firms with a EVH price target in the last 12 months, the median target is $7. Stephens's target matches it.
- Current rating
- Overweight
- Price target
- $7
- Median target, all firms
- $7
- Actions on EVH
- 3
Stephens price target on EVH
Every Stephens rating on EVH
- Nov 13, 2025
- Nov 8, 2024
- Apr 12, 2023
How other firms rate EVH
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Citigroup | Buy | $6 | Aug 11, 2026 |
| Truist Securities | Hold | $7 | Jun 30, 2026 |
| KeyBanc Capital Markets | Sector Weight | Feb 25, 2026 | |
| Stephens | Overweight | $7 | Nov 13, 2025 |
| BMO Capital Markets | Outperform | $7 | Nov 13, 2025 |
Questions about Stephens and EVH
- What is Stephens's price target for EVH?
- Stephens's latest stated price target for Evolent Health Inc (EVH) is $7, from its action on Nov 13, 2025.
- What is Stephens's rating on EVH?
- Stephens rates EVH Overweight, a bullish rating, as of Nov 13, 2025.
- When did Stephens last change its view on EVH?
- On Nov 13, 2025, Stephens upgrades to Overweight from Equal-Weight, price target $7.
- How does Stephens's EVH target compare with other analysts?
- Across 4 firms with a EVH price target in the last 12 months, the median target is $7. Stephens's target matches it.
More EVH rating histories
All Stephens ratingsEVH news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.